"An investment in knowledge pays the best interest."


Revive Therapeutics Ltd. (RVV.V) has initiated a research discovery program of cannabinoid-based therapeutics targeting liver diseases. The preclinical studies, including in vitro and in vitro pharmacology, will be conducted by PhytoSciences Consulting LLC, a contract research organization in Louisville, Kentucky. This novel investigation will be overseen by academic scientists with over 20 years' experience with expertise in liver disease research.

The Company's discovery research program will initially employ an in vivo compound screening approach to investigate cannabinoids in a fibrosis model. The cell-based ligand screening is a targeted experimental approach that will involve approximately eighty cannabinoids utilizing a number of validated models for liver diseases. Based on the results of the compound screen, the Company will advance to performing preclinical studies by employing validated in vitro animal models with the cannabinoids that demonstrated in vivo efficacy for specific liver diseases. The overall objective of these studies is to identify cannabinoids for the potential treatments of a number of well-known and rare diseases that the Company may advance to the clinic and potentially partner with pharmaceutical companies.

"This is a very exciting step we are embarking on in our commitment to innovate and discover novel cannabinoids as potential treatments in a number of liver diseases," said Craig Leon, Chief Executive Officer of Revive. "We will be advancing the discovery program immediately and we expect to uncover potential cannabinoids to treat those liver diseases that are in desperate need of safe and effective treatments."

"I am very excited to execute on the initial work that has taken place in such a short time in discovering potentially novel ground-breaking cannabinoid-based treatments for liver diseases," said Dr. Pritesh Kumar, Scientific Advisor for the Company and Chief Executive Officer of PhytoSciences Consulting LLC. "The opportunities for cannabinoids and liver diseases are endless and this is an area where we have significant drug discovery and development expertise."

About Liver Disease

Liver disease is described by irregular functioning of liver, causing disorders like hepatitis, fatty liver, and cirrhosis. There are over 100 described diseases of the liver affecting at least 30 million people alone in the U.S. A number of factors are driving the liver disease treatment market, which include rapidly changing lifestyle patterns such as increasing alcohol consumption, unhealthy diets, and increasing prevalence of liver diseases. Liver diseases can result from injury to the liver caused by hepatitis C virus (HCV), hepatitis B virus (HBV), obesity, chronic excessive alcohol use or autoimmune diseases. Major drug categories used in the treatment of liver diseases includes anti-rejection drugs, vaccines, immunosuppressant, chemotherapy drugs and antiviral drugs. According to Allied Market Research, titled, "World Liver Disease Treatment Market - Opportunities and Forecast, 2014 - 2022", the global market for liver disease treatment is projected to reach $19,536 million by 2022.

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) is focused on the research, development and commercialization of novel treatments for serious and unmet medical needs by identifying and investigating potential drugs and plant-based therapies, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities or prodrugs. Additional information on Revive is available at www.ReviveThera.com.